The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...
FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...
Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...
UH engineers helped develop an mRNA-based strategy that boosts cancer-fighting T cells and, in mouse studies, helped ...
In a new study published in Nature Immunology, researchers at Boston Children's Hospital demonstrated that pairing the original COVID-19 mRNA vaccine with an immune system enhancer, known as an ...
While the approved vaccines aimed at neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have proven effective in decreasing the risk of severe infection and mortality, it may ...
Cemiplimab significantly improves DFS in patients with high-risk CSCC post-surgery, reducing recurrence or death risk by 68% compared with placebo. The C-POST trial marks the first immunotherapy to ...
Risk-Adjusted Mortality Rates as a Quality Proxy Outperform Volume in Surgical Oncology—A New Perspective on Hospital Centralization Using National Population-Based Data The Finland Capecitabine Trial ...
Three-month adjuvant capecitabine and oxaliplatin treatment can be considered an option for some patients with high-risk stage II colon cancer. More recently, the practice of adjuvant chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results